SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics
TRIL 20.39+1.0%Nov 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (55)8/31/2017 7:22:04 PM
From: tuck1 Recommendation

Recommended By
mopgcw

  Read Replies (1) of 294
 
>>>> asked by the company to change its business description in the subject header <<

Tacky. Wish they had better things to do.<<

Well, they managed to keep themselves occupied for almost a year. They diluted shareholders to expand the SIRPa program (into PD1 combo, getting to be a crowded space) and rationalized the Fluorinov assets.

Other than that, no exciting data since then, unless one considers a dose reduction exciting. Maybe they're prepping something better to say at this year's ASH (not a peep at ESMO).

But until then, thumb twiddling, I guess, as they've found time to ask me to update the header again per their specs. I'll do it, but if they want it done without snark next time, they need to deliver more good news than bad.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News